Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07621718 · ClinicalTrials.gov registry record · Phase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
A Phase 3 study, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT07621718 is a Phase 3 study that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 670 participants.
The verdict
NCT07621718, a Phase 3 study, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Interventions
- DRUG Placebo
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
- DRUG Zoldonrasib
- DRUG Leucovorin (Calcium Folinate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2030-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07621718
The ClinicalTrials.gov registry entry for NCT07621718 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07621718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07621718 about?
NCT07621718 is a clinical study titled "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )". The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
What is the current status of trial NCT07621718?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2026-05-22. Estimated completion is 2030-04-22.
What interventions are being tested in trial NCT07621718?
The interventions under investigation include: Placebo (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG), Zoldonrasib (DRUG), Leucovorin (Calcium Folinate) (DRUG).
Who is sponsoring clinical trial NCT07621718?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.